New shot could replace daily pills for advanced prostate cancer
NCT ID NCT07005154
First seen Nov 01, 2025 · Last updated May 02, 2026 · Updated 20 times
Summary
This study tests a new injectable form of the hormone therapy abiraterone (ASP5541) in men with advanced prostate cancer that has spread. The shot is given every 12 weeks, instead of daily pills. The goal is to see if it works as well as or better than the standard pill, and to check its safety. About 218 men with either hormone-sensitive or castration-resistant metastatic prostate cancer will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Associated Urological Specialists
RECRUITINGChicago Ridge, Illinois, 60415, United States
-
Carolina Urologic Research Center
RECRUITINGMyrtle Beach, South Carolina, 29572, United States
-
Clearview Cancer Institute
RECRUITINGHuntsville, Alabama, 35805, United States
-
H. Lee Moffitt Cancer Center
RECRUITINGTampa, Florida, 33612, United States
-
Harasanshin Hospital
RECRUITINGFukuoka, Japan
-
Huai'an First People's Hospital
RECRUITINGHuaian, 211731, China
-
National Cancer Center Hospital East
RECRUITINGKashiwa, Chiba, Japan
-
New Mexico Oncology Hematology Consultants
RECRUITINGAlbuquerque, New Mexico, 87109, United States
-
Nippon Medical School Hospital
RECRUITINGBunkyo-ku, Tokyo, Japan
-
Ochsner Health - Ochsner Medical Center - New Orleans
RECRUITINGNew Orleans, Louisiana, 70121, United States
-
Osaka International Cancer Institute
RECRUITINGOsaka, Japan
-
PanOncology Trials
RECRUITINGSan Juan, Puerto Rico
-
Renji Hospital Shanghai Jiaotong Univ School of Medicine
RECRUITINGShanghai, 200127, China
-
Shizuoka Cancer Center
RECRUITINGSunto-gun, Shizuoka, Japan
-
Site DE49001
RECRUITINGHeinsberg, Germany
-
Site DE49004
RECRUITINGNürtingen, Baden-Wurttemberg, Germany
-
Site ES34006
RECRUITINGBarcelona, Catalonia, Spain
-
Site FR33004
RECRUITINGStrasbourg, France
-
Site GB44003
RECRUITINGLondon, United Kingdom
-
Site KR82002
RECRUITINGSeoul, South Korea
-
Site KR82003
RECRUITINGSeoul, South Korea
-
Site KR82004
RECRUITINGSeoul, South Korea
-
Site KR82007
RECRUITINGSeoul, South Korea
-
Site KR82008
RECRUITINGGwangju, South Korea
-
Site TW88602
RECRUITINGTaipei, Taiwan
-
Site TW88603
RECRUITINGKaohsiung City, Taiwan
-
Solaris Health - The Urology Group
RECRUITINGCincinnati, Ohio, 45212, United States
-
Subei People's Hospital
RECRUITINGYangzhou, Jiangsu, 225001, China
-
Tennessee Oncology Nashville
RECRUITINGNashville, Tennessee, 37203, United States
-
The Cancer Institute Hospital of JFCR
RECRUITINGKoto, Tokyo, Japan
-
The Second Hospital of Tianjin Medical University
RECRUITINGTianjin, Tianjin Municipality, 300211, China
-
UW Health Carbone Cancer Center
RECRUITINGMadison, Wisconsin, 53792, United States
-
University of Virginia Cancer Center
RECRUITINGCharlottesville, Virginia, 22908-07, United States
Conditions
Explore the condition pages connected to this study.